Actinium Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, Iomab-B that is in a pivotal Phase III clinical trial as an induction and conditioning agent in patients over the age of 55 with relapsed or refractory acute myeloid leukemia prior to receiving a bone marrow transplant, also known as a hematopoietic stem cell transplant.
Read More…
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone+1-646-6773875
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees30
Next Earnings Date11/8/2019 (Estimated)
OptionableOptionable
Actinium Pharmaceuticals (NYSEAMERICAN:ATNM) Frequently Asked Questions
What is Actinium Pharmaceuticals' stock symbol?
Actinium Pharmaceuticals trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "ATNM."
How were Actinium Pharmaceuticals' earnings last quarter?
Actinium Pharmaceuticals Inc (NYSEAMERICAN:ATNM) announced its quarterly earnings results on Friday, August, 9th. The biotechnology company reported ($0.03) earnings per share for the quarter. View Actinium Pharmaceuticals' Earnings History.
When is Actinium Pharmaceuticals' next earnings date?
What price target have analysts set for ATNM?
4 brokers have issued 1-year price targets for Actinium Pharmaceuticals' shares. Their forecasts range from $3.00 to $6.00. On average, they expect Actinium Pharmaceuticals' share price to reach $4.67 in the next twelve months. This suggests a possible upside of 2,262.9% from the stock's current price. View Analyst Price Targets for Actinium Pharmaceuticals.
What is the consensus analysts' recommendation for Actinium Pharmaceuticals?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Actinium Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Actinium Pharmaceuticals.
What are Wall Street analysts saying about Actinium Pharmaceuticals stock?
Here are some recent quotes from research analysts about Actinium Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It specializes in the development of cancer drugs. The company's principal product candidates under different developmental stages include Actimab-A for the treatment of acute myeloid leukemia in elderly patients and Iomab-B used to condition the bone marrow of patients. Actinium Pharmaceuticals, Inc. is based in New York. " (6/4/2019)
- 2. Maxim Group analysts commented, "Actinium reported 4Q18 and FY18 with a net loss of ($6.4M) and ($23.7M), respectively. The company ended the year with $13.6M in cash on the balance sheet (not including $2.5M warrant exercises). The company also has a $30M ATM in place. Combined, the company should have sufficient runway to get the P3 data for Iomab in 1H20." (3/20/2019)
Has Actinium Pharmaceuticals been receiving favorable news coverage?
Media headlines about ATNM stock have trended negative recently, InfoTrie Sentiment Analysis reports. The research group ranks the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Actinium Pharmaceuticals earned a daily sentiment score of -2.6 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Actinium Pharmaceuticals.
Are investors shorting Actinium Pharmaceuticals?
Actinium Pharmaceuticals saw a increase in short interest in September. As of September 30th, there was short interest totalling 3,510,000 shares, an increase of 16.2% from the August 30th total of 3,020,000 shares. Based on an average trading volume of 626,400 shares, the days-to-cover ratio is presently 5.6 days. Approximately 2.2% of the shares of the stock are sold short. View Actinium Pharmaceuticals' Current Options Chain.
Who are some of Actinium Pharmaceuticals' key competitors?
Some companies that are related to Actinium Pharmaceuticals include Verseon (VSN), CorMedix (CRMD), Fennec Pharmaceuticals (FRX), Burcon NutraScience (BU), Matinas BioPharma (MTNB), Antibe Therapeutics (ATE), Sirona Biochem (SBM), Medlab Clinical (MDC), OncoCyte (OCX), OncoCyte (OCX), Immutep (IMM), 4d Pharma (DDDD), Helix Biopharma (HBP), Oxford Biodynamics (OBD) and IntelGenx Technologies (IGX).
What other stocks do shareholders of Actinium Pharmaceuticals own?
Who are Actinium Pharmaceuticals' key executives?
Actinium Pharmaceuticals' management team includes the folowing people:
- Mr. Sandesh C. Seth, Chairman & CEO (Age 55)
- Mr. Steven O'Loughlin BS, Principal Financial & Accounting Officer (Age 33)
- Dr. Dale L. Ludwig Ph.D., Chief Scientific Officer (Age 57)
- Dr. Mark S. Berger, Chief Medical Officer (Age 64)
- Mr. Anil Kapur, Chief Commercial Officer (Age 50)
How do I buy shares of Actinium Pharmaceuticals?
Shares of ATNM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Actinium Pharmaceuticals' stock price today?
One share of ATNM stock can currently be purchased for approximately $0.20.
How big of a company is Actinium Pharmaceuticals?
What is Actinium Pharmaceuticals' official website?
How can I contact Actinium Pharmaceuticals?
Actinium Pharmaceuticals' mailing address is 275 Madison Avenue, 7Th Floor, NEW YORK, NY 10016, United States. The biotechnology company can be reached via phone at +1-646-6773875.
MarketBeat Community Rating for Actinium Pharmaceuticals (NYSEAMERICAN ATNM)
MarketBeat's community ratings are surveys of what our community members think about Actinium Pharmaceuticals and other stocks. Vote "Outperform" if you believe ATNM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ATNM will underperform the S&P 500 over the long term. You may vote once every thirty days.
